FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Date/App# patent app List of recent Receptor-related patents
08/21/14
20140236057
 Methods and devices for treating hypertension patent thumbnailnew patent Methods and devices for treating hypertension
Devices, systems and methods are described which control blood pressure and nervous system activity by stimulating baroreceptors. By selectively and controllably activating baroreceptors and/or nerves, the present invention reduces blood pressure and alters the sympathetic nervous system; thereby minimizing deleterious effects on the heart, vasculature and other organs and tissues.
08/21/14
20140235864
 Biphenyl derivatives patent thumbnailnew patent Biphenyl derivatives
Wherein r1, r2, r3, r4, r5, r6, r7, w, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma..
08/21/14
20140235841
 Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity patent thumbnailnew patent Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsrna) having specific biological activities, which includes acting as a selective agonist for activation of the toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation).
08/21/14
20140235790
 Carbohydrate-based compositions and methods for targeted drug delivery patent thumbnailnew patent Carbohydrate-based compositions and methods for targeted drug delivery
Provided herein are compositions and methods for intracellular delivery. The compositions are polymer compositions in which the polymer serves as a carrier for therapeutic and/or diagnostic agents.
08/21/14
20140235726
 Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor patent thumbnailnew patent Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
A method of improving cognition in a patient with down syndrome, which entails administering one or more β2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests. .
08/21/14
20140235723
 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses patent thumbnailnew patent Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
08/21/14
20140235719
 Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin patent thumbnailnew patent Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin
The present invention relates to the novel use (anti-inflammatory activity) of ramalin isolated from the antarctic lichen ramalina terebrata, and more specifically to a pharmaceutical composition containing ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (inos) in the transcription stage to significantly inhibit the production of nitric oxide (no) that is a key mediator of inflammatory responses.
08/21/14
20140235717
 Food products, preparation, and therapeutic methods patent thumbnailnew patent Food products, preparation, and therapeutic methods
A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a western diet..
08/21/14
20140235672
 Chromene modulators of chemokine receptor activity patent thumbnailnew patent Chromene modulators of chemokine receptor activity
Or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein w1, w2, w3, y, z, r2, r3, r3′ and r4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
08/21/14
20140235661
 New ccr2 receptor antagonists and uses thereof patent thumbnailnew patent New ccr2 receptor antagonists and uses thereof
The present invention relates to novel antagonists for ccr2 (cc chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and copd.. .
08/21/14
20140235660
new patent Compounds and compositions as selective estrogen receptor degraders
In which n, m, x, y1, r1, r2, r3, r4 and r5 are defined in the summary of the invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity..
08/21/14
20140235623
new patent Modulation of chemosensory receptors and ligands associated therewith
The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands. The present invention also includes modifiers of chemosensory receptors and their ligands having formula (i), its subgenus, and specific compounds.
08/21/14
20140235622
new patent Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
The present invention also relates to the methods for the treatment of 5-ht2a serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.. .
08/21/14
20140235613
new patent Substituted diaryl azetidine derivatives as sphingosine receptor modulators
The present invention relates to substituted diaryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/21/14
20140235610
new patent Use of s1p receptor modulator
Use of an s1p receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (bdnf) expression.. .
08/21/14
20140235609
new patent Carbamate/urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors
The invention relates to compound of the formula i (i) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation and to medicaments comprising it for treating diseases connected to tehinhibition of h3 receptor.. .
08/21/14
20140235606
new patent Crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6--4-pyrimidinyl]-1-azetidinesulfonamide
There is provided crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial..
08/21/14
20140235602
new patent Compositions and methods for suppressing endometrial proliferation
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (serm) therapy.
08/21/14
20140235599
new patent Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
The present invention relates to compositions and methods for the treatment of the charcot-marie-tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signalling and thyroid hormone pathway in a subject..
08/21/14
20140235592
new patent Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
The present invention relates to substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides derivatives, processes for preparing them, pharmaceutical compositions to containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/21/14
20140235591
new patent Bicyclic compounds
And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.
08/21/14
20140235588
new patent Substituted 1h-pyrazol-1,2,4-oxadiazole derivatives as sphingosine receptor modulators
The present invention relates to substituted 1h-pyrazol-1,2,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/21/14
20140235587
new patent Substituted pyrazoles as sphingosine receptor modulators
The present invention relates to substituted pyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/21/14
20140235585
new patent Substituted diaryl derivatives as sphingosine receptor modulators
The present invention relates to substituted diaryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/21/14
20140235576
new patent Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
The present invention relates to compounds of formula (i), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iglur receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iglur receptors.. .
08/21/14
20140235564
new patent Methods for treating neural cell swelling
A composition comprising a novel ca2+-activated, [atp]i-sensitive nonspecific cation (ncca-atp) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [ca]i.
08/21/14
20140235556
new patent Compositions and methods of treating gliomas
The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (il-1) inhibitor, a cyclooxygenase inhibitor, an α2δ voltage-dependent calcium channel (vdcc) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-ht agonist, an angiotensin-converting enzyme (ace) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent.
08/21/14
20140235546
new patent Novel peptide inhibitors of serotonin 5-ht2c receptors:pten interaction
The 5-ht 2c receptor is implicated in feeding, obesity, palatable food reward, metabolic disorders, drug addiction, anxiety, stress sensitivity, and depression. Embodiments of the invention are directed to modulation of the 5 -ht 2cr.
08/21/14
20140235544
new patent Disease treatment via antimicrobial peptides or their inhibitors
The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (amp) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous amps or that compete with pro-inflammatory agents or fragments of amps on cognate receptors without inducing disease..
08/21/14
20140235534
new patent Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
08/21/14
20140235494
new patent Methods, kits and computer program products using hepatocellular carcinoma (hcc) biomarkers
Methods of determining the presence or risk of liver disease or other diseases in a subject include measuring a level of a saccharide selected from n-acetylneuraminic acid, n-acetylglucosamine, n-acetylgalactosamine, or a combination thereof on one or more glycosylated proteins and the total amount of alpha-fetoprotein in a biological sample from the subject. Glycosylated proteins include but are not limited to vascular endothelial growth factor, lymphatic vessel endothelial hyaluronan receptor, e-cadherin, alpha 1 acid glycoprotein, glypican-3, galectin-3, and any combination thereof.
08/21/14
20140235482
new patent Immunoglobulin fc polypeptides
Methods and compositions involving polypeptides having an aglycosylated antibody fc domain. In certain embodiments, polypeptides have an aglycosylated fc domain that contains one or more substitutions compared to a native fc domain.
08/21/14
20140234961
new patent Synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle containing fusion proteins for targeted introduction of sirna
A fusion protein and process are provided by which double-stranded rna containing small interfering rna nucleotide sequences is introduced into specific cells and tissues. A cell surface receptor specific synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle specific to a cell surface receptor of the cell and having a cell surface receptor specific binding site is provided.
08/21/14
20140234943
new patent Viruses lacking epithelial cell receptor entry
The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients.
08/21/14
20140234868
new patent Use for glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medical-plant derived ligand
The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on lpa1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), lpa2, lpa3, lpa4 and lpa5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [lpa1(edg-2), lpa2(edg-4), lpa3(edg-7), lpa4, pla5] in the edg (endothelial differentiation gene) family in g protein-coupled receptors (gpcrs) present in the cell membranes of animals including humans. The gintonin of the present invention can be used to advantage in the prevention and treatment of various diseases arising from reduced calcium concentration and various physiological activities and pharmaceutical activities dependent on calcium, since the gintonin of the present invention interacts with lpa receptors so as to activate a series of signal transmission processes and temporarily induce an increase in free ca2+ in the cytoplasm, and a temporary increase in the intracellular calcium concentration gives rise to a temporary increase in the intracellular calcium concentration in various organs including, inter alia, those of the nervous system, cardiovascular system, endocrine system, reproductive system, digestive system and immune system when the lpa receptors are expressed, with physiological activity being exhibited..
08/21/14
20140234866
new patent Ex vivo flow cytometry method and device
Wherein the group ab comprises a ligand that binds to the pathogenic cells and the group x comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.. .
08/21/14
20140234859
new patent Controlled platelet activation to monitor therapy of adp antagonists
A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or gpiib/iiia blockade. A blood sample is obtained from the individual being assessed.
08/21/14
20140234851
new patent Modular extracellular sensor architecture for cell-based biosensors
The present invention provides modular extracellular sensors, nucleic acids encoding such sensors, and cells expressing such sensors, and methods of employing such sensors and cells for detecting extracellular ligands. In certain embodiments, the extracellular sensors comprise a ligand binding domain, a transmembrane domain, a protease domain, a protease cleavage site, and a transcription factor.
08/21/14
20140234766
new patent Toner to develop electrostatic latent images
A toner t1 develops an electrostatic latent image, the toner t1 having relieved charge-up characteristics, improved development characteristics, and improved transfer characteristics. The toner t1 may ensure high charge stability against environmental condition changes, and an appropriate amount of charges at a high printing speed, may reduce background contamination on a photoreceptor, may prevent undesirable fusing onto a blade even after prolonged printing, and may have high transfer efficiency and high image uniformity.
08/21/14
20140234728
new patent Electrolyte for secondary battery and lithium secondary battery including the same
Disclosed are an electrolyte for a lithium secondary battery which includes a non-aqueous solvent and a lithium salt, wherein the non-aqueous solvent includes an anion receptor, a cyclic carbonate, and a linear solvent, wherein an amount of the cyclic carbonate is in a range of 1 wt % to 30 wt % based on a total weight of the non-aqueous solvent, and a lithium secondary battery including the same.. .
08/21/14
20140234443
new patent 5-ht3 receptor modulators, methods of making, and use thereof
Novel 5-ht3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome.
08/21/14
20140234376
new patent Substituted benzoazepines as toll-like receptor modulators
Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease..
08/21/14
20140234348
new patent Universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
The invention provides compositions and methods for adoptive t cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (univir) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain..
08/21/14
20140234330
new patent Il-17 receptor a is required for il-17c biology
The present invention relates to interleukin-17 ligand and receptor family members and the discovery that il-17 receptor a and il-17 receptor e form a heteromeric receptor complex that is biologically active, and that il-17c activity requires the il-17ra-il-17re heteromeric receptor complex. Antagonists of the il-17ra-il-17re heteromeric receptor complex are disclosed, as well as various methods of use..
08/21/14
20140234329
new patent Antibodies against the ectodomain of erbb3 and uses thereof
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of erbb3 receptor and inhibit various erbb3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated erbb3 and inhibiting egf-like ligand mediated phosphorylation of the receptor.
08/21/14
20140234328
new patent Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
The present invention relates to use of the human met receptor (also known as “c-met”) for predicting the efficacy of inhibitors of the hgf-met pathway, and in particular, anti-hgf antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-hgf antibodies in the treatment of esophageal and gastric cancer..
08/21/14
20140234323
new patent Compositions and methods for detecting tlr3
The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to tlr3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect tlr3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects..
08/21/14
20140234322
new patent Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
08/21/14
20140234314
new patent Antibodies against epidermal growth factor receptor (egfr) and uses thereof
Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
08/21/14
20140234308
new patent Treatment of breast cancer with companion diagnostic
Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the brca1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (her-2/neu), which accounts for approximately half of all breast cancer deaths.
08/21/14
20140234297
new patent Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140234296
new patent Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
The present invention relates to stable formulations of antibodies against human programmed death receptor pd-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor pd-1, or antigen binding fragments thereof..
08/21/14
20140234294
new patent Fibroblast growth factor receptor-derived peptides binding to ncam
The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of ncam. The peptides are peptide fragments of fgfrs.
08/21/14
20140234245
new patent N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use
N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides of formula (1) are described that are potent modulators (e.g., inhibitors) of an androgen receptor, and which are useful, for example, in the treatment of a dermatological disease or disorder; a disease or disorder of the sebaceous gland(s); acne; hyperseborrhoea; oily skin, seborrhoeic dermatitis; hyperpilosity or hirsutism; atopic dermatitis; or androgenic alopecia; especially acne. Also described, are compositions (e.g., pharmaceutical compositions, cosmetic compositions) comprising the compounds; methods of preparing the compositions; methods of modulating (e.g., inhibiting) and androgen receptors using the compounds and/or compositions; and medical and/or cosmetic use of the compounds and compositions..
08/21/14
20140234213
new patent Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
Methods for generating hybrid antibodies are provided.. .
08/21/14
20140234211
new patent Supramolecular aggregates containing amphiphilic monomers, chelating agents and peptides for use for drug delivery and as contrast agents
Delivery systems based on liposomes functionalized with peptides and chelating agents, for therapy and imaging by selective targeting of tumour cells expressing the receptors grp, bb1, bb2, bb3 e bb4 and any other receptor which recognizes the bombesin peptide or analogues thereof are described. In particular, the liposomes contain within them cytotoxic drugs, such as for example doxorubicin, for target-selective antitumour therapy, and, through the presence of the chelating agent, can contain radioactive or paramagnetic ions for the real time visualization of the tumour cells.
08/21/14
20140233983
new patent Electrophotographic photoreceptor
An electrophotographic photoreceptor is removably installed and used in a device main unit of an electrophotography application device so as to form a process cartridge. The device main unit includes a driving-side power transmission portion.
08/21/14
20140233075
new patent Counterfeit deterrence using full width array scans
Systems and methods are described that facilitate counterfeit deterrence in a printer or the like. A final image is scanned from a photoreceptor belt before or after transfer of the image to a print medium or from the print medium itself prior to output, and the scanned image data is assessed using a set of stored criteria to detect counterfeit signatures in the scanned image.
08/14/14
20140229115
Methods for diagnosing diseases and evaluating treatments therefor using pet
The present invention relates to methods for determining whether a mammal has a disease, such as diabetes, using pet data analysis techniques. These methods include administering to a mammal a pet-compatible tracer, such as a radioligand specific for a vesicular monoamine transporter 2 (vmat2) receptor, and measuring total functional β-cell capacity (volume) of the mammal's pancreas using pet data analysis techniques.
08/14/14
20140228721
Methods and devices for treating hypertension
Devices, systems and methods are described which control blood pressure and nervous system activity by stimulating baroreceptors. By selectively and controllably activating baroreceptors and/or nerves, the present disclosure reduces blood pressure and alters the sympathetic nervous system; thereby minimizing deleterious effects on the heart, vasculature and other organs and tissues.
08/14/14
20140228568
Biphenyl derivatives, pharmaceutical composition comprising the same, and preparation method thereof
Provided are biphenyl derivatives exhibiting activity towards central nervous system diseases by acting on the 5-ht7 receptor, pharmaceutically acceptable salts thereof, a method for preparing the compounds and pharmaceutical compositions including the compounds as an active ingredient.. .
08/14/14
20140228565
Thienopyrimidinone derivatives as mglur1 antagonists
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as parkinson's disease and alzheimer's disease.
08/14/14
20140228445
Alkyne derivatives as sphingosine 1-phosphate (s1p) receptor modulators
The present invention relates to alkyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/14/14
20140228441
Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications
The invention relates to compounds of formula (i), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (i).
08/14/14
20140228439
Ketone compounds and compositions for cholesterol management and related uses
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing alzheimer's disease, syndrome x, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence.
08/14/14
20140228406
Fentanyl derivatives as ph-dependent opioid receptor agonists
The invention relates to fluorinated fentanyl derivatives that function as opioid receptor agonists, which activate target opioid receptors in a ph-dependent manner, and are thus selective for the receptors in inflamed (acidic) milieu; uses thereof and pharmaceutical compositions comprising them.. .
08/14/14
20140228402
Combinations comprising a s1p receptor modulator
The invention relates to a combination which comprises fingolimod and at least antidepressant compound.. .
08/14/14
20140228398
Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease
The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in parkinson's disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.. .
08/14/14
20140228395
N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors
The present invention relates to novel n-(imidazolidin-2-ylidene)-heterocyclo penta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.. .
08/14/14
20140228380
Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from parkinson's disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing parkinson's disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention..
08/14/14
20140228377
Methylpiperidine derivative
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .
08/14/14
20140228375
Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity
The present invention involves new and original sigma receptors ligands: (mono-or dialkylaminoalkyl)-γ-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the n,n dialkyl α-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and quinacrine me-thylene blue, asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.. .
08/14/14
20140228362
Method of treatment or prophylaxis
The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin ii receptor 2 (at2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects.
08/14/14
20140228355
Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from parkinson's disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing parkinson's disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention..
08/14/14
20140228353
Compounds and methods of treating diabetes
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2a.
08/14/14
20140228345
Substituted pyrazole azetidines as sphingosine receptor modulators
The present invention relates to substituted pyrazole azetidines, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/14/14
20140228344
Alkene azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
The present invention relates to alkene azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/14/14
20140228342
Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics
Methods for treating hypopigmentary pathologies and photosensitive dermatoses are described. Also described, are compounds that are agonists of the mcir receptor and that exhibit reduced toxicity relative to other compounds of the same class.
08/14/14
20140228341
Azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/14/14
20140228339
Novel compound
The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.. .
08/14/14
20140228331
Compositions of protein receptor tyrosine kinase inhibitors
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, tropomysosin related kinases (trk), in particular the nerve growth factor (ngf) receptor, trka. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of ngf receptor trka..
08/14/14
20140228325
Alkene derivatives as sphingosine 1-phosphate (s1p) receptor modulators
The present invention relates to alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/14/14
20140228324
Substituted dihydropyrazoles as sphingosine receptor modulators
The present invention relates to substituted dihydropyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
08/14/14
20140228315
Blockade of eosinophil production by toll-like receptors
It has long been known that eosinopenia is observed during acute bacterial infection yet the mechanism remains undefined. Herein, we investigated the consequence of exposure to microbial products, specfically bacterial lipopolysaccharide (lps), on eosinophil production.
08/14/14
20140228299
Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
The present invention provides an agent for neurological disease, the agent comprising lipoprotein containing apolipoprotein e as the active substance thereof, in which a neuroprotective system via activation of neuroprotective molecules and/or the inactivation of neurodegeneration-inducing molecules, mediated by lipoprotein receptors, may work as a mechanism, and a prophylactic and therapeutic method for neurological diseases. The lipoproteins containing apolipoprotein e and/or neuroprotective system through, as the action mechanism, the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors have prophylactic and therapeutic effects of, including, inhibiting nerve cell apoptosis, on neurological disease such as various neurodegenerative diseases accompanied by nerve cell apoptosis as the essential condition.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5284

4408

1 - 1 - 97